Existing treatment options for these cancers are limited, and no small-molecule inhibitors of gankyrin have been published to date; a broad-spectrum histone deacetylase inhibitor LBH589 is known to affect the proliferative and metastatic potential of gankyrin over-expressing HCCs, but it lacks selectivity6. The gene discussed is PSMD10; the disease is cancer.